Germline EGFR mutations and familial lung cancer
Geoffrey R Oxnard,Ruthia Chen,Jennifer C Pharr,Diane R Koeller,Arrien A Bertram,Suzanne E Dahlberg,Irene Rainville,Kate Shane-Carson,Kelly A Taylor,Alicia Sable-Hunt,Lynette M Sholl,Craig C Teerlink,Alun Thomas,Lisa A Cannon-Albright,André P Fay,Patrícia Ashton-Prolla,Hao Yang,Mary M Salvatore,Bonnie J Addario,Pasi A Jänne,David P Carbone,Georgia L Wiesner,Judy E Garber,Geoffrey R. Oxnard,Jennifer C. Pharr,Diane R. Koeller,Arrien A. Bertram,Suzanne E. Dahlberg,Kelly A. Taylor,Lynette M. Sholl,Craig C. Teerlink,Lisa A. Cannon-Albright,André P. Fay,Mary M. Salvatore,Bonnie J. Addario,Pasi A. Jänne,David P. Carbone,Georgia L. Wiesner,Judy E. Garber
DOI: https://doi.org/10.1200/jco.23.01372
IF: 45.3
2023-08-14
Journal of Clinical Oncology
Abstract:BACKGROUND The genomic underpinnings of inherited lung cancer risk are poorly understood. This prospective study characterized the clinical phenotype of patients and families with germline EGFR pathogenic variants (PVs). METHODS The INHERIT study (NCT01754025) enrolled lung cancer patients whose tumor profiling harbored possible germline EGFR PVs and their relatives, either in-person or remotely, providing germline testing and follow-up. RESULTS 141 participants were enrolled over a 5-year period, 100 (71%) remotely. Based upon prior genotyping, 116 participants from 59 kindreds were tested for EGFR T790M, consistent with a pattern of Mendelian inheritance with variable lung cancer penetrance. In confirmed or obligate carriers of a germline EGFR PV from 39 different kindreds, 50/91 (55%) were affected with lung cancer with 34/65 (52%) diagnosed by age 60. Somatic testing of lung cancers in carriers revealed that 35 of 37 (95%) had an EGFR driver co-mutation. Among 36 germline carriers without a cancer diagnosis, 15 had CT imaging and 9 had lung nodules, including a 28-year-old with >10 lung nodules. Given geographic enrichment of germline EGFR T790M in the Southeast United States, genome-wide haplotyping of 46 germline carriers was performed and identified a 4.1 Mb haplotype shared by 41 (89%), estimated to originate 223-279 years ago. CONCLUSIONS In this first prospective description of familial EGFR-mutant lung cancer, we identify a recent founder germline EGFR T790M variant enriched in the US Southeast. The high prevalence of EGFR-driver lung adenocarcinomas and lung nodules in germline carriers supports effort to identify affected patients and family members for investigation of CT-based screening for these high-risk individuals.
oncology